Reboxetine augmentation of fluoxetine for patients with major depressive disorder: An 8-week open-label study

被引：0
|
作者：
Rapaport, M
Wilcox, C
Heiser, J
Londborg, P
Schwartz, G
机构：
[1] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA
[2] Pharmacol Res Inst, Los Alamitos, CA USA
[3] Summit Res Network, Seattle, WA USA
来源：
EUROPEAN NEUROPSYCHOPHARMACOLOGY | 2002年 / 12卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：S205 / S205
页数：1
相关论文
共 50 条
  • [41] Sertraline and periodic limb movements during sleep: an 8-week open-label study in depressed patients with insomnia
    Zhang, Bin
    Hao, Yanli
    Jia, Fujun
    Li, Xueli
    Ren, Yanzhen
    Zhou, Ping
    Liu, Wuhan
    Wing, Yun Kwok
    SLEEP MEDICINE, 2013, 14 (12) : 1405 - 1412
  • [42] Randomized, 8-week, double-blind, placebo-controlled trial of vortioxetine in Japanese adults with major depressive disorder, followed by a 52-week open-label extension trial
    Inoue, Takeshi
    Nishimura, Akira
    Sasai, Kiyofumi
    Kitagawa, Tadayuki
    PSYCHIATRY AND CLINICAL NEUROSCIENCES, 2018, 72 (02) : 103 - 115
  • [43] Sertraline and rapid eye movement sleep without atonia: An 8-week, open-label study of depressed patients
    Zhang, Bin
    Hao, Yanli
    Jia, Fujun
    Tang, Yi
    Li, Xueli
    Liu, Wuhan
    Arnulf, Isabelle
    PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2013, 47 : 85 - 92
  • [44] An open-label, flexible-dose study of memantine in major depressive disorder
    Ferguson, James M.
    Shingleton, Richard N.
    CLINICAL NEUROPHARMACOLOGY, 2007, 30 (03) : 136 - 144
  • [45] Open-label tiagabine monotherapy for major depressive disorder with anxiety
    Carpenter, LL
    Schecter, JM
    Tyrka, AR
    Mello, AF
    Mello, MF
    Haggarty, R
    Price, LH
    JOURNAL OF CLINICAL PSYCHIATRY, 2006, 67 (01) : 66 - 71
  • [46] STX209 (Arbaclofen) for Autism Spectrum Disorders: An 8-Week Open-Label Study
    Erickson, Craig A.
    Veenstra-Vanderweele, Jeremy M.
    Melmed, Raun D.
    McCracken, James T.
    Ginsberg, Lawrence D.
    Sikich, Linmarie
    Scahill, Lawrence
    Cherubini, Maryann
    Zarevics, Peter
    Walton-Bowen, Karen
    Carpenter, Randall L.
    Bear, Mark F.
    Wang, Paul P.
    King, Bryan H.
    JOURNAL OF AUTISM AND DEVELOPMENTAL DISORDERS, 2014, 44 (04) : 958 - 964
  • [47] STX209 (Arbaclofen) for Autism Spectrum Disorders: An 8-Week Open-Label Study
    Craig A. Erickson
    Jeremy M. Veenstra-Vanderweele
    Raun D. Melmed
    James T. McCracken
    Lawrence D. Ginsberg
    Linmarie Sikich
    Lawrence Scahill
    Maryann Cherubini
    Peter Zarevics
    Karen Walton-Bowen
    Randall L. Carpenter
    Mark F. Bear
    Paul P. Wang
    Bryan H. King
    Journal of Autism and Developmental Disorders, 2014, 44 : 958 - 964
  • [48] Acute phase management of schizophrenia with aripiprazole: A 8-week open-label prospective study in korea
    Cho, S.
    Kwon, J. S.
    Youn, T.
    Kang, D. H.
    SCHIZOPHRENIA BULLETIN, 2007, 33 (02) : 425 - 426
  • [49] LURASIDONE FOR THE TREATMENT OF MAJOR DEPRESSIVE DISORDER WITH MIXED FEATURES: RESULTS OF A 12-WEEK OPEN-LABEL EXTENSION STUDY
    Stahl, S. M.
    Pikalov, A.
    Tocco, M.
    Mao, Y.
    Loebel, A.
    Hopwood, M.
    AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY, 2019, 53 : 145 - 146
  • [50] Lurasidone for the treatment of major depressive disorder with mixed features: results of a 12-week open-label extension study
    Stahl, S. M.
    Pikalov, A.
    Tocco, M.
    Mao, Y.
    Loebel, A.
    EUROPEAN PSYCHIATRY, 2019, 56 : S94 - S94
12345